Recent Updates
Recently added Catalysts

Androgenetic Alopecia: two biotech companies racing to a treatment

Immunology & InflammationConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$2.8Buniverse median $1.20B
Allocated capital$5.6B$5.6B competing
Phase 3 or filed10 mid, 1 early
Pure plays2this indication only
Capital rank34/299crowding rank 71

Androgenetic Alopecia is a two-horse race: Veradermics (MANE, $4.1B) against Absci (ABSI, $1.5B).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $5.6B of allocated capital sits on the pair.

MANE carries 73% of the $5.6B competing here, so the pair is far from evenly matched.

$5.6B of allocated capital sits in Androgenetic Alopecia, 34th of 299 indications, and 2 of the 2 companies are pure plays that trade on this indication alone.

Companies developing drugs for Androgenetic Alopecia 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
MANEVeradermicsVDPHL01Phase 34$4.1BYes1 31 Dec 2026
ABSIAbsciABS-201 Single DosePhase 12$1.5BYes1 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. MANE holds 73% of the $5.6B competing in this indication.

Why Androgenetic Alopecia is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Androgenetic Alopecia has 2 competitors and a median of $2.8B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Idiopathic Pulmonary Fibrosis7 companies · $5.8B · median $1.3BGold rushCrohn's Disease4 companies · $5.1B · median $714MOrphan cornerSjögren's Disease4 companies · $4.4B · median $1.7BConcentrated betSystemic Lupus Erythematosus13 companies · $7.2B · median $1.2BKnife fightThyroid Eye Disease2 companies · $3.6B · median $2.8BConcentrated betIgA Nephropathy4 companies · $3.6B · median $1.8BConcentrated betUlcerative Colitis6 companies · $8.5B · median $1.8BGold rushRheumatoid Arthritis9 companies · $8.6B · median $1.7BGold rush

Androgenetic Alopecia pipeline questions

Which biotech companies are developing drugs for Androgenetic Alopecia?

Veradermics (MANE, VDPHL01, Phase 3); Absci (ABSI, ABS-201 Single Dose, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Androgenetic Alopecia.

How advanced is the Androgenetic Alopecia pipeline?

Of the 2 clinical-stage programmes in Androgenetic Alopecia, 1 is in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Which company leads the Androgenetic Alopecia field?

MANE is the largest developer in Androgenetic Alopecia, holding 73% of the $5.6B of market capitalisation competing in the indication. The median competitor is worth $2.8B.

When is the next Androgenetic Alopecia catalyst?

The next dated catalyst in Androgenetic Alopecia is MANE on 31 Dec 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map